Cell-free DNA in the supernatant of pleural effusion as bio-source for diagnostic biomarker tests 223 6 Molecular diagnostics performed in clinical practice Time of sampling Clinical application Assay Results Tumor cell percentage (estimated by pathologist on Giemsa slide) progressive disease during erlotinib treatment molecular profiling + T790M NGS EGFR L858R NO T790M 5% unknown sanger seq KRAS 10% 20% 20% progressive disease during erlotinib treatment 30% 50% 60% 60% 60% unknown progressive disease during gefitinib treatment T790M not possible <5% <5% 10-20% molecular profiling + T790M NGS EGFR exon 19 del NO T790M 20-80% 40-50% high
RkJQdWJsaXNoZXIy MTk4NDMw